Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids

被引:21
作者
de Haan, EC
Wauben, MHM
Grosfeld-Stulemeyer, MC
Kruijtzer, JAW
Liskamp, RMJ
Moret, EE
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Med Chem, NL-3508 TB Utrecht, Netherlands
[2] Univ Utrecht, Dept Infect Dis & Immunol, Immunol Div, NL-3508 TD Utrecht, Netherlands
关键词
D O I
10.1016/S0968-0896(01)00434-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The major histocompatibility complex (MHC) class 11 binding requirements for solvent-exposed peptide residues were systematically studied using amino acid and peptoid substitutions. In a peptoid residue, the side chain is present on the backbone nitrogen atom as opposed to the alpha-carbon atom in an amino acid residue. To investigate the effect of this side chain shifting on MHC binding, three amino acids in the central part of the peptide sticking out of the binding groove were replaced by corresponding peptoid residues, Two peptoid-peptide hybrids showed large affinity decreases in the MHC-peptide binding assay. To investigate this affinity loss, the individual contributions to MHC binding affinity of the side chain (position), the putative hydrogen bond, and the flexibility were dissected. We conclude that the side chain position as well as the backbone nitrogen atom hydrogen bonding features of solvent-exposed residues in the peptide can be important for MHC binding affinity. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1939 / 1945
页数:7
相关论文
共 25 条
[1]   NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains [J].
Armand, P ;
Kirshenbaum, K ;
Goldsmith, RA ;
Farr-Jones, S ;
Barron, AE ;
Truong, KTV ;
Dill, KA ;
Mierke, DF ;
Cohen, FE ;
Zuckermann, RN ;
Bradley, EK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4309-4314
[2]   Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures [J].
Bolin, DR ;
Swain, AL ;
Sarabu, R ;
Berthel, SJ ;
Gillespie, P ;
Huby, NJS ;
Makofske, R ;
Orzechowski, L ;
Perrotta, A ;
Toth, K ;
Cooper, JP ;
Jiang, N ;
Falcioni, F ;
Campbell, R ;
Cox, D ;
Gaizband, D ;
Belunis, CJ ;
Vidovic, D ;
Ito, K ;
Crowther, R ;
Kammlott, U ;
Zhang, XL ;
Palermo, R ;
Weber, D ;
Guenot, J ;
Nagy, Z ;
Olson, GL .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (11) :2135-2148
[3]  
Calbo S, 1999, J IMMUNOL, V162, P4657
[4]   SELECTION OF ENCEPHALITOGENIC RAT LYMPHOCYTE-T CLONES RECOGNIZING AN IMMUNODOMINANT EPITOPE ON MYELIN BASIC-PROTEIN [J].
CHOU, YK ;
VANDENBARK, AA ;
JONES, RE ;
HASHIM, G ;
OFFNER, H .
JOURNAL OF NEUROSCIENCE RESEARCH, 1989, 22 (02) :181-187
[5]   Structure-based design and evaluation of MHC class II binding peptides [J].
de Haan, EC ;
Wauben, MHM ;
Grosfeld-Stulemeyer, MC ;
Moret, EE .
BIOLOGICALS, 2001, 29 (3-4) :289-292
[6]  
Ettouati L, 1996, PEPTIDE RES, V9, P248
[7]   Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules [J].
Falcioni, F ;
Ito, K ;
Vidovic, D ;
Belunis, C ;
Campbell, R ;
Berthel, SJ ;
Bolin, DR ;
Gillespie, PB ;
Huby, N ;
Olson, GL ;
Sarabu, R ;
Guenot, J ;
Madison, V ;
Hammer, J ;
Sinigaglia, F ;
Steinmetz, M ;
Nagy, ZA .
NATURE BIOTECHNOLOGY, 1999, 17 (06) :562-567
[8]  
Hin S, 1999, J IMMUNOL, V163, P2363
[9]  
Howard SC, 1997, PROTEIN PEPTIDE LETT, V4, P63
[10]   Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides [J].
Jardetzky, TS ;
Brown, JH ;
Gorga, JC ;
Stern, LJ ;
Urban, RG ;
Strominger, JL ;
Wiley, DC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :734-738